Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft model

Journal of Neuro-Oncology

Volumn 92, Issue 1, 2009, Pages 23-31

  Kitange, Gaspar J ^a   Carlson, Brett L ^a   Mladek, Ann C ^a   Decker, Paul A ^a   Schroeder, Mark A ^a   Wu, Wenting ^a   Grogan, Patrick T ^a   Giannini, Caterina ^a   Ballman, Karla V ^a   Buckner, Jan C ^a   David James, C ^b   Sarkaria, Jann N ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Glioblastoma; Methylation; MGMT; Orthotopic xenografts

Indexed keywords

BISULFITE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PLACEBO; TEMOZOLOMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CPG ISLAND; DNA METHYLATION; DRUG RESPONSE; DRUG SENSITIVITY; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; MOUSE; NONHUMAN; NUDE MOUSE; ORTHOTOPIC TRANSPLANTATION; POLYMERASE CHAIN REACTION; PROMOTER REGION; PROTEIN EXPRESSION; QUANTITATIVE STUDY; SEQUENCE ANALYSIS; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; BASE SEQUENCE; BLOTTING, WESTERN; BRAIN NEOPLASMS; DACARBAZINE; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION; GLIOBLASTOMA; HUMANS; MICE; MICE, NUDE; MOLECULAR SEQUENCE DATA; POLYMERASE CHAIN REACTION; PROMOTER REGIONS, GENETIC; TUMOR SUPPRESSOR PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 59349101857     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-008-9737-8     Document Type: Article

References (30)

1. Liu L, Gerson SL (2006) Targeted modulation of MGMT: Clinical implications. Clin Cancer Res 12:328-331. doi: 10.1158/ 1078-0432.CCR-05-2543
2. Paz MF, Yaya-Tur R, Rojas-Marcos I, Reynes G, Pollan M, Aguirre-Cruz L, Garcia-Lopez JL, Piquer J, Safont MJ, Balana C, Sanchez-Cespedes M, Garcia-Villanueva M, Arribas L, Esteller M (2004) CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas. Clin Cancer Res 10:4933-4938. doi: 10.1158/1078-0432.CCR-04-0392
3. Esteller M, Hamilton SR, Burger PC, Baylin SB, Herman JG (1999) Inactivation of the DNA repair gene o 6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 59:793-797
4. Hegi ME, Diserens A-C, Gorlia T, Hamou M-F, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JEC, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997-1003. doi: 10.1056/NEJMoa043331
5. Sarkaria JN, Yang L, Grogan PT, Kitange GJ, Carlson BL, Schroeder MA, Galanis E, Giannini C, Wu W, Dinca EB, James CD (2007) Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel. Mol Cancer Ther 6:1167-1174. doi: 10.1158/1535-7163.MCT-06-0691
6. Sarkaria JN, Carlson BL, Schroeder MA, Grogan P, Brown PD, Giannini C, Ballman KV, Kitange GJ, Guha A, Pandita A, James CD (2006) Use of an orthotopic xenograft model for assessing the effect of epidermal growth factor receptor amplification on glioblastoma radiation response. Clin Cancer Res 12:2264-2271. doi: 10.1158/1078-0432.CCR-05-2510
7. Giannini C, Sarkaria J, Saito A, Uhm J, Galanis E, Carlson B, Schroeder M, James C (2005) Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of GBM. Neuro-oncol 7:164-176. doi: 10.1215/S1152851704000821
8. Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, Baylin SB, Herman JG (2000) Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343:1350-1354. doi: 10.1056/NEJM200011093431901
9. Matsukura S, Soejima H, Nakagawachi T, Yakushiji H, Ogawa A, Fukuhara M, Miyazaki K, Nakabeppu Y, Sekiguchi M, Mukai T (2003) CpG methylation of MGMT and hMLH1 promoter in hepatocellular carcinoma associated with hepatitis viral infection. Br J Cancer 88:521-529. doi: 10.1038/ sj.bjc.6600743
10. Kokkinakis DM, Bocangel DB, Schold SC, Moschel RC, Pegg AE (2001) Thresholds of o 6-alkylguanine-DNA alkyltransferase which confer significant resistance of human glial tumor xenografts to treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea or temozolomide. Clin Cancer Res 7:421-428
11. Leuraud P, Taillandier L, Medioni J, Aguirre-Cruz L, Criniere E, Marie Y, Kujas M, Golmard J-L, Duprez A, Delattre J-Y, Sanson M, Poupon M-F (2004) Distinct responses of xenografted gliomas to different alkylating agents are related to histology and genetic alterations. Cancer Res 64:4648-4653. doi: 10.1158/0008-5472.CAN-03-3429
12. Middlemas DS, Stewart CF, Kirstein MN, Poquette C, Friedman HS, Houghton PJ, Brent TP (2000) Biochemical correlates of temozolomide sensitivity in pediatric solid tumor xenograft models. Clin Cancer Res 6:998-1007
13. Friedman HS, Dolan ME, Pegg AE, Marcelli S, Keir S, Catino JJ, Bigner DD, Schold SC Jr (1995) Activity of temozolomide in the treatment of central nervous system tumor xenografts. Cancer Res 55:2853-2857
14. Pandita A, Aldape KD, Zadeh G, Guha A, James CD (2003) Contrasting in vivo and in vitro fates of glioblastoma cell subpopulations with amplified EGFR. Genes Chromosomes Cancer 39:29-36. doi: 10.1002/gcc.10300
15. Hegi ME, Diserens A-C, Godard S, Dietrich P-Y, Regli L, Ostermann S, Otten P, Van Melle G, de Tribolet N, Stupp R (2004) Clinical trial substantiates the predictive value of o -6-Methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 10:1871-1874. doi: 10.1158/ 1078-0432.CCR-03-0384
16. Friedman HS, McLendon RE, Kerby T, Dugan M, Bigner SH, Henry AJ, Ashley DM, Krischer J, Lovell S, Rasheed K, Marchev F, Seman AJ, Cokgor I, Rich J, Stewart E, Colvin OM, Provenzale JM, Bigner DD, Haglund MM, Friedman AH, Modrich PL (1998) DNA mismatch repair and o 6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. J Clin Oncol 16:3851-3857
17. Rodriguez FJ, Thibodeau SN, Jenkins RB, Schowalter KV, Caron BL, O'Neill BP, James CD, Passe S, Slezak J, Giannini C (2008) MGMT immunohistochemical expression and promoter methylation in human glioblastoma. Appl Immunohistochem Mol Morphol 16:59-65
18. Qian X, von Wronski MA, Brent TP (1995) Localization of methylation sites in the human o 6-methylguanine-DNA methyltransferase promoter: correlation with gene suppression. Carcinogenesis 16:1385-1390. doi: 10.1093/carcin/16.6.1385
19. Watts GS, Pieper RO, Costello JF, Peng YM, Dalton WS, Futscher BW (1997) Methylation of discrete regions of the o 6-methylguanine DNA methyltransferase (MGMT) CpG island is associated with heterochromatinization of the MGMT transcription start site and silencing of the gene. Mol Cell Biol 17:5612-5619
20. Herfarth KK, Brent TP, Danam RP, Remack JS, Kodner IJ, Wells SA Jr, Goodfellow PJ (1999) A specific CpG methylation pattern of the MGMT promoter region associated with reduced MGMT expression in primary colorectal cancers. Mol Carcinog 24:90-98. doi:10.1002/ (SICI)1098-2744(199902)24:2<90::AID-MC3>3.0.CO;2-B
21. Yamada H, Vijayachandra K, Penner C, Glick A (2001) Increased sensitivity of transforming growth factor (TGF) beta 1 null cells to alkylating agents reveals a novel link between TGFbeta signaling and o (6)-methylguanine methyltransferase promoter hypermethylation. J Biol Chem 276:19052-19058. doi: 10.1074/jbc.M100615200
22. Danam RP, Howell SR, Remack JS, Brent TP (2001) Heterogeneous methylation of the o (6)-methylguanine-DNA methyltransferase promoter in immortalized IMR90 cell lines. Int J Oncol 18:1187-1193
23. Vlassenbroeck I, Califice S, Diserens AC, Migliavacca E, Straub J, Di Stefano I, Moreau F, Hamou MF, Renard I, Delorenzi M, Flamion B, Diguiseppi J, Bierau K, Hegi ME (2008) Validation of real-time methylation-specific PCR to determine o 6-methylguanine-DNA methyltransferase gene promoter methylation in glioma. J Mol Diagn 10:332-337. doi: 10.2353/jmoldx.2008.070169
24. Danam RP, Howell SR, Brent TP, Harris LC (2005) Epigenetic regulation of o 6-methylguanine-DNA methyltransferase gene expression by histone acetylation and methyl-CpG binding proteins. Mol Cancer Ther 4:61-69
25. Ballestar E, Esteller M, Ballestar E, Esteller M (2005) Methyl-CpG-binding proteins in cancer: Blaming the DNA methylation messenger. Biochem Cell Biol 83:374-384. doi: 10.1139/o05-035
26. Fraga MF, Ballestar E, Montoya G, Taysavang P, Wade PA, Esteller M, Fraga MF, Ballestar E, Montoya G, Taysavang P, Wade PA, Esteller M (2003) The affinity of different MBD proteins for a specific methylated locus depends on their intrinsic binding properties. Nucleic Acids Res 31:1765-1774. doi: 10.1093/nar/gkg249
27. Sekimata M, Homma Y, Sekimata M, Homma Y (2004) Sequence-specific transcriptional repression by an MBD2-interacting zinc finger protein MIZF. Nucleic Acids Res 32:590-597. doi: 10.1093/nar/gkh249
28. Mancini DN, Rodenhiser DI, Ainsworth PJ, O'Malley FP, Singh SM, Xing W, Archer TK (1998) CpG methylation within the 5′ regulatory region of the BRCA1 gene is tumor specific and includes a putative CREB binding site. Oncogene 16:1161-1169. doi: 10.1038/sj.onc.1201630
29. Chien J, Staub J, Avula R, Zhang H, Liu W, Hartmann LC, Kaufmann SH, Smith DI, Shridhar V (2005) Epigenetic silencing of TCEAL7 (Bex4) in ovarian cancer. Oncogene 24:5089-5100. doi: 10.1038/sj.onc.1208700
30. Costello JF, Futscher BW, Kroes RA, Pieper RO (1994) Methylation-related chromatin structure is associated with exclusion of transcription factors from and suppressed expression of the o-6-methylguanine DNA methyltransferase gene in human glioma cell lines. Mol Cell Biol 14:6515-6521